Silence Therapeutics PLC
OTC:SLNCF

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
OTC:SLNCF
Watchlist
Price: 5.79 USD 3.39% Market Closed
Market Cap: 812.9m USD
Have any thoughts about
Silence Therapeutics PLC?
Write Note

Silence Therapeutics PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Silence Therapeutics PLC
Operating Income Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Silence Therapeutics PLC
OTC:SLNCF
Operating Income
-ÂŁ22.7m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$171.3m
CAGR 3-Years
-154%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Income
-$175.5m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Income
-$196.5m
CAGR 3-Years
-45%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ59.6m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ54.2m
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
4%

See Also

What is Silence Therapeutics PLC's Operating Income?
Operating Income
-22.7m GBP

Based on the financial report for Dec 31, 2019, Silence Therapeutics PLC's Operating Income amounts to -22.7m GBP.

What is Silence Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-24%

Over the last year, the Operating Income growth was -11%. The average annual Operating Income growth rates for Silence Therapeutics PLC have been -24% over the past three years .

Back to Top